Physician profile
Edward J Doyle
NPI 1558362822
$3,289.65
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $482 · 2021: $498 · 2022: $344 · 2023: $1,319 · 2024: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892 · Travel and Lodging: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.02 |
| Travel and Lodging | $603.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $611.23 | 2023 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Astrazeneca Pharmaceuticals LP | $442.04 | 2019-2024 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $422.25 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $373.58 | 2022-2024 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $171.45 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $170.85 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $159.19 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.02 | 2020-2023 | Jardiance, Tradjenta, Synjardy |
| Sunovion Pharmaceuticals INC. | $104.96 | 2019-2022 | |
| Pfizer INC. | $94.99 | 2019-2021 | |
| Eisai INC. | $74.40 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.89 | 2019-2021 | |
| Astellas Pharma US INC | $52.14 | 2019-2022 | |
| Amarin Pharma, INC. | $51.74 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $48.99 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $45.74 | 2023 | Auvelity |
| Exact Sciences Corporation | $43.73 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $40.46 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $38.83 | 2023 | Gvoke Hypopen |
| Kaleo, INC. | $37.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.34 | 2021 | |
| Grifols USA, LLC | $30.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.88 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.63 | 2022 | |
| Amgen INC. | $15.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.65 | 2021 | |
| Sumitomo Pharma America, INC. | $6.77 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.